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Activation of macrophages with stimuli of the innate immune response results in the 
intense remodeling of arachidonate-containing phospholipids, leading to the 
mobilization of large quantities of this fatty acid for conversion into biologically active 
eicosanoids. As a consequence of this process, the arachidonate levels in membrane 
phospholipids markedly decrease. We have applied mass spectrometry-based lipid 
profiling to study the levels of arachidonate-containing phospholipids under 
inflammatory activation of macrophages. We identify an unusual inositol phospholipid 
molecule, PI(20:4/20:4), the levels of which do not decrease but actually increase by 
300% after activation of the macrophages. PI(20:4/20:4) is formed and degraded 
rapidly, suggesting a role for this molecule in regulating cell signaling events. Using a 
metabolipidomic approach consisting in exposing the cells to deuterium-labeled 
arachidonate at the time they are exposed to stimuli, we show that PI(20:4/20:4) 
biosynthesis occurs via the sequential incorporation of arachidonate, first into the sn-2 
position of a preformed phosphatidylinositol molecule, followed by the rapid 
introduction of a second arachidonate moiety into the sn-1 position. Generation 
requires the participation of cytosolic phospholipase A2α and CoA-dependent 
acyltransferases. PI(20:4/20:4) formation is also detected in vivo in murine peritonitis 
exudates. Elevating the intracellular concentration of PI(20:4/20:4) by introducing the 
lipid into the cells results in enhancement of the microbicidal capacity of macrophages, 
as measured by reactive oxygen metabolite production and lysozyme release. These 
findings suggest that PI(20:4/20:4) is a novel bioactive inositol phospholipid molecule 
that regulates innate immune responses in macrophages. 
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The mobilization of arachidonic acid (20:4)2 from membrane phospholipids is one of 
the earliest events that occur after stimulation of macrophages with innate stimuli 
such as the phagocytosable particle zymosan [1-3]. Zymosan is a cell-wall preparation 
of Saccharomyces cerevisiae that is widely used as a model stimulus for macrophage 
activation [1-6]. Zymosan is composed of β-glucan, mannans, mannoproteins, and 
chitin, and is recognized by multiple macrophage receptors, including dectin-1, toll-like 
receptor 2, complement receptor 3, mannose receptors, and scavenger receptors [7,8]. 
 Part of the 20:4 liberated in response to zymosan and other stimuli is 
oxygenated by cyclooxygenase and lipoxygenase pathways to generate a number of 
biologically active eicosanoids, while the rest is effectively incorporated back into 
phospholipids by the action of CoA-dependent acyltransferases [9, 10]. There is now 
solid evidence that activation of intracellular phospholipase A2 (PLA2)  enzymes, in 
particular the calcium-dependent cytosolic group IV PLA2 (cPLA2α) provides the major 
route for effecting the 20:4 release [9-12], and that the major zymosan receptor 
involved in this process is dectin-1 [13-15]. 
 cPLA2α has been found to translocate to the phagosomes after stimulation of 
the phagocytes, and such a translocation appears to be key for eicosanoid generation 
and killing of the ingested microbe [16-18]. The enzyme is regulated post-
translationally by increases in intracellular calcium levels and by phosphorylation [10]. 
The intracellular calcium level regulates the ability of cPLA2α to associate to cellular 
membranes, which is mediated by a C2 domain present at the N-terminal half of the 
protein. The C2 domain also contains a site for binding to ceramide-1-phosphate, 
which allosterically activates the enzyme and increases the residence time of the 
enzyme in membranes [19]. The enzyme also possesses a binding site for anionic 
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phospholipids, particularly phosphatidylinositol 4,5-bisphosphate, that may also be 
involved in anchoring the cPLA2α to cellular membranes [20-22]. Phosphorylation of 
cPLA2α is known to be effected by members of the mitogen-activated protein kinase 
family of enzymes, i.e. the extracellular signal-regulated kinases p42/p44, p38, and c-
Jun N-terminal kinase, although the specific form involved appears to strikingly depend 
on cell type and stimulus [10]. In murine macrophages, the kinases responsible for 
cPLA2α phosphorylation/activation have been found to be p42/p44 [6, 23]. 
 Studies on 20:4 mobilization under activation conditions have traditionally 
relied upon the use of cells or tissues pre-labeled with radioactive fatty acid and 
measurement of radioactivity levels in different fractions after addition of the 
simulant. While these types of studies have been very useful to delineate biochemical 
pathways and enzymes involved, they were not devoid of complications derived from 
lack of homogeneous labeling among phospholipid pools and impossibility to detect 
specific molecular species [9, 24, 25]. The development of liquid chromatography/mass 
spectrometry (LC/MS)-based techniques to the study of lipids has allowed these 
shortcomings to be solved, since lipids in samples, even those present at relatively low 
concentrations, can be efficiently separated and identified with great sensitivity [9, 24-
28]. 
 Our laboratory has been applying LC/MS phospholipid profiling to the study of 
the metabolism of 20:4-containing phospholipids during cell activation [9, 29-34]. Our 
goal has been to define the molecular sources for 20:4 liberation and incorporation, 
and to relate this information with the activation of particular phospholipase forms by 
stimuli of the innate immune response. Here we have extended the use of LC/MS to 
characterize 20:4-containing phospholipids that increase their levels during zymosan 
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phagocytosis in macrophages. We show the stimulated formation of an uncommon PI 
molecule, PI(20:4/20:4), and delineate the pathway of biosynthesis as well as its 
biological role in regulating innate immune responses. 
 
Materials and Methods 
Reagents –  Cell culture medium was from Molecular Probes-Invitrogen (Carlsbad, CA). 
Chloroform and methanol (HPLC grade) were from Fisher Scientific (Hampton, NH). 
PI([2H]20:4/20:4) and PI(20:4/[2H]20:4) were purchased from Cayman Chemical (Ann 
Arbor, MI). Lipid standards were from Avanti Polar Lipids (Alabaster, AL) or Larodan 
Fine Chemicals (Malmö, Sweden). Triacsin C was from Enzo Life Sciences (Farmingdale, 
NY). The cPLA2α inhibitor pyrrophenone was synthesized and generously provided by 
Dr. Amadeu Llebaria (Institute for Chemical and Environmental Research, Barcelona, 
Spain). All other reagents were from Sigma-Aldrich. 
 
Cell culture – Resident peritoneal macrophages from Swiss male mice (University of 
Valladolid Animal House, 10-12 week old) were obtained by peritoneal lavage using 5 
ml of cold PBS, as described elsewhere [4, 5]. The cells were plated at 2 x 106 per well 
(6-well plates) in 2 ml of RPMI with 10% heat inactivated serum, 100 units/ml penicillin 
and 100 µg/ml streptomycin, and allowed to adhere for 20 h in a humidified 
atmosphere of 5% CO2 at 37oC. Wells were then extensively washed with PBS to 
remove non-adherent cells. Adherent macrophages were then used for 
experimentation. When inhibitors were used, they were added to the incubation 
media 30 min before stimulating the cells with zymosan. For inducing peritonitis, mice 
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were injected i.p. with 1 mg zymosan in 500 µl of sterile saline. Control mice received 
vehicle only. After the indicated times, mice were euthanized in a CO2 chamber, and 
peritoneal exudates were collected by lavaging with 5 ml of sterile saline. Exudate cells 
were obtained by centrifugation. All procedures involving animals were undertaken in 
accordance with the Spanish National Committee on Biosafety and Animal Care, under 
the guidelines established by the Spanish Ministry of Agriculture, Food and 
Environment, and the European Union. 
 
Preparation of zymosan – Zymosan was prepared as described elsewhere [35]. Briefly, 
zymosan particles were suspended in PBS, boiled for 60 min, and washed three times. 
The final pellet was resuspended in PBS at 20 mg/ml and stored frozen. Zymosan 
aliquots were diluted in serum-free medium and sonicated before addition to the cells. 
For preparation of opsonized zymosan, zymosan particles, treated as indicated above, 
were incubated with fresh mouse serum (10 mg zymosan per ml serum) for 20 min at 
37°C, and washed three times with PBS before use. No endogenous phospholipase A2 
activity was detected in the zymosan batches used in this study, as assessed by in vitro 
assay under a variety of conditions [36-39]. 
 
LC/MS analysis of 20:4-containing phospholipids – A cell extract corresponding to 107 
cells was used for these analyses. The following internal standards were added: 600 
pmol each of 1,2-dipentadecanoyl-sn-glycero-3-phosphocholine, 1,2-dilauroyl-sn-
glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoinositol, and 
1,2-dimyristoyl-sn-glycero-3-phosphoserine, before lipid extraction according to the 
method of Bligh and Dyer [40]. After evaporation of organic solvent under vacuum, the 
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lipids were redissolved in 100 μl of methanol/water (9:1, v/v) and injected into a high-
performance liquid chromatograph equipped with a binary pump Hitachi LaChrom Elite 
L-2130 and a Hitachi Autosampler L-2200 (Merck). The column was a Supelcosil LC-18 
(5 μm particle size, 250×2.1 mm) (Sigma-Aldrich) protected with a Supelguard LC-18 
(20×2.1 mm) guard cartridge (Sigma-Aldrich). Mobile phase was a gradient of solvent A 
(methanol/water/n-hexane/32% ammonium hydroxide, 87.5:10.5:1.5:0.5, v/v/v/v) and 
solvent B (methanol/n-hexane/32% ammonium hydroxide, 87.5:12:0.5, v/v/v). The 
gradient was started at 100% solvent A; it was decreased linearly to 65% solvent A, 
35% solvent B in 20 min, to 10% solvent A, 90% solvent B in 5 min, and to 0% solvent A, 
100% solvent B in an additional 5 min. Flow rate was 0.5 ml/min, and 80 μl of the lipid 
extract was injected. The liquid chromatography system was coupled online to a Bruker 
esquire6000 ion-trap mass spectrometer (Bruker Daltonics, Bremen, Germany). The 
total flow rate into the column was split and 0.2 ml/min entered into the electrospray 
interface of the mass spectrometer. Nebulizer gas was set to 30 psi, dry gas to 7 l/min 
and dry temperature to 325°C. PE, PI and PS were detected in negative ion mode with 
the capillary current set at +3500 V over the initial 25 min as [M−H]− ions. PC species 
were detected over the elution interval from 25 to 35 min in positive ion mode, as 
[M+H]+ ions, with the capillary current set at −3500 V. 
 20:4-Containing PE, PI and PS species were identified by multiple reaction 
monitoring MS/MS experiments on chromatographic effluent by comparison with 
previously published data [29-34]. Cut off parameter was set at m/z 150 and 
fragmentation amplitude at 1 arbitrary unit. Because of the lability of vinyl ether 
linkages in acid media, plasmanyl (1-alkyl) and plasmenyl (1-alk-1'-enyl) 
glycerophospholipids were distinguished by acidifying the samples before lipid 
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extraction. For the identification of acyl chains of 20:4-containing PC species, ionization 
was carried out in negative mode with post-column addition of acetic acid at a flow 
rate of 100 μl/h as [M+CH3CO2]− adducts, and acyl chains were identified by MS3 
experiments. Stereospecific assignation of fatty acyl chains was carried out by 
comparing the relative intensities of the 1-lysophospholipid and 2-lysophospholipid 
compounds arising in the fragmentation experiments (the signal of the latter 
predominates over that of the former in ion trap mass spectrometry) [29-34]. 
 
Incorporation of PI(20:4/20:4) Into Cells – 2 µg of phospholipid was mixed with 2 µl of 
carrier (histone H1, 0.5 mM); resuspended in 200 µl of Hank’s balanced salt solution 
containing 10 mM HEPES, and 1.3 mM CaCl2; sonicated in a water bath for 2 min; and 
allowed to rest at 37°C for 10 min before use. Final concentration of PI(20:4/20:4) in 
the solution was 10 µM. 
 
Quantitative PCR – Quantitative PCR was carried out with an ABI 7500 machine 
(Applied Biosystems, Carlsbad, CA) using the Brilliant III Ultra-Fast SYBR® Green QPCR 
Master Mix (Agilent Technologies, Santa Clara, CA) and specific primers for each gene 
of interest. Cycling conditions were: 1 cycle at 95°C for 3 min and 40 cycles at 95°C for 
12 s, 60°C for 15 s and 72°C for 28 s. The relative mRNA abundance for a given gene 
was calculated using the algorithm 2-∆∆Ct , with  β-actin and cyclophilin A as internal 
standards [41]. 
 
Superoxide anion production – The production of superoxide anion was measured by 
the superoxide dismutase-inhibitable reduction of ferricytochrome c in a discontinuous 
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assay. 2x106 cells were preincubated for 5 min at 37°C with cytochalasin B (5 µg/ml) in 
a final volume of 1 ml of a glucose-containing buffer (10 mM Hepes, 150 mM NaCl, 1.2 
mM MgCl2, 1.3 mM CaCl2, 5.5 mM glucose, pH 7.5) containing 0.9 mg/ml of 
cytochrome c in the presence or absence of 10 µg/ml of superoxide dismutase. Then, 
the appropriate stimulus was added and the reaction proceeded for 1 h at 37°C. When 
PI(20:4/20:4) was used, it was added 30 min before the addition of the stimulus. 
Afterward, samples were centrifuged to remove cells and the supernatants were 
collected. The extent of cytochrome c reduction was measured at 550 nm. The 
difference in absorbance between superoxide dismutase-treated and –untreated 
samples was a measure of the amount of reduced cytochrome c. Controls with 
superoxide dismutase (10 µg/ml) were run in parallel to ensure that cytochrome c 
reduction was due only to the superoxide anion generated during cell stimulation. 
 
Lysozyme release assay – Lysozyme content in cell supernatants was determined by 
measuring the rate of clearance of a suspension of M. lysodeikticus, as described 
elsewhere [42]. Briefly, the cells (2x106 cells/ml) were placed in a glucose-containing 
buffer (10 mM Hepes, 150 mM NaCl, 1.2 mM MgCl2, 1.3 mM CaCl2, 5.5 mM glucose, pH 
7.5). Then, the appropriate stimulus was added and the reaction proceeded for 1 h at 
37°C. When PI(20:4/20:4) was used, it was added 30 min before the addition of the 
stimulus. Afterward, the supernatants were collected, and 1 ml was mixed with 1 ml of 
a M. lysodeikticus suspension (0.3 mg/ml in 0.1 M sodium phosphate buffer, pH 7.0). 
The decrease in absorbance at 450 nm was measured at room temperature. A 
calibration curve was constructed using chicken egg white lysozyme as a standard, and 
run in parallel with the supernatant samples.  
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Results 
Profiling of 20:4-containing phospholipids in activated macrophages – The profile of 
20:4-containing glycerophospholipid species of murine peritoneal macrophages was 
measured by LC/ ion-trap MS. The lipids were unequivocally identified by determining 
the production of a m/z 303 fragment in MSn experiments, corresponding to 20:4. 
Structural identification of the glycerophospholipids was achieved by looking at the 
fragments and/or neutral losses obtained in MS2 experiments for PE, PI and PS or MS3 
experiments for PC [29-34]. A total of 23 different phospholipid species were detected 
(Fig. 1A). Fatty chains within phospholipids are designated by their number of carbons : 
double bonds. A designation of O- before the first fatty chain indicates that the sn-1 
position is ether-linked, while a P- designation indicates a plasmalogen form (sn-1 vinyl 
ether linkage) [43]. The major 20:4-containing species of the peritoneal macrophages 
were, in this order: PE(P-16:0/20:4), PC(16:0/20:4), PE(18:0/20:4), PC(18:0/20:4), PE(P-
18:0/20:4), PI(18:0/20:4), PS(18:0/20:4), and PC(18:1/20:4). Regarding classes, PE was 
the richest 20:4-containing class (48% of total cellular fatty acid), followed by PC (36%), 
PI (9%), and PS (7%). (Fig. 1B). 
 Stimulation of the macrophages with zymosan resulted in a significant 
diminution of the total cellular content of 20:4 in phospholipids. Analyses of the 
species that lost 20:4 after stimulation revealed that many, but not all phospholipid 
species contributed to this release (Figs. 1C,D). Most PC species and the species 
PI(18:0/20:4) experienced similarly strong decreases, while PS species decreased to a 
much lesser extent. Conversely, no PE species showed a significant decrease (Figs. 
1C,D). Interestingly however, two minor 20:4-containing species not only did not 
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decrease or remained unchanged, but actually increased after zymosan stimulation. 
These were two diarachidonoylated species, PC(20:4/20:4) and, most prominently, 
PI(20:4/20:4).  
 
Identification of the pathway involved in PI(20:4/20:4) production – While cellular 
increases in PC(20:4/20:4) were described some 25 years ago [44], the increase in 
PI(20:4/20:4) after cell activation is a novel and striking finding, which prompted us to 
characterize it in detail. The time-course of production of PI(20:4/20:4) shows that 
PI(20:4/20:4) proceeded linearly up to 1 h after zymosan stimulation, decreasing 
afterward, and remaining elevated over basal even after 2 h stimulation with zymosan 
(Fig. 2A). 
 To study the route of synthesis of PI(20:4/20:4) during cellular stimulation, a 
metabolipidomic experiment was designed where the cells were pulsed with a low 
[2H]20:4 concentration at the time they were stimulated with zymosan. Analysis by 
LC/MS of deuterium-containing phospholipids formed after 30 min demonstrated the 
stimulated presence of PI([2H]20:4/[2H]20:4), along with the following species: 
PC(16:0/[2H]20:4), PC(18:0/[2H]20:4), PC(18:1/[2H]20:4), PI(18:0/[2H]20:4), 
PI(16:0/[2H]20:4), and PC([2H]20:4/[2H]20:4). Interestingly, a PI(20:4/20:4) molecule 
containing deuterium in only one 20:4 chain was also found (Fig. 2B, m/z 913.6). This 
species was unequivocally identified as PI([2H]20:4/20:4) in MS/MS experiments by 
comparison with an authentic standard. The PI species containing [2H]20:4 at the sn-2 
position but not at the sn-1 position (PI(20:4/[2H]20:4)) was not detected, nor was it 
any other phospholipid containing deuterium only at the sn-1 position. No deuterium-
containing lysophospholipids were detected either. Taken together, these findings 
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suggest that PI(20:4/20:4) is formed via fatty acid exchange at both the sn-2 and sn-1 
positions through direct deacylation/reacylation reactions (i.e the Lands cycle).  
 In the Lands cycle, fatty acids at the sn-2 position of phospholipids are cleaved 
by PLA2 and replaced with 20:4 by the sequential action of arachidonoyl-CoA 
synthetase and lysophospholipid:acyl-CoA acyltransferase [10, 45].  Hence, if this is the 
route for PI(20:4/20:4) synthesis by the zymosan-activated macrophages, production of 
this phospholipid should be sensitive to inhibitors of these enzymes. Fig. 2C shows that 
the increase in PI(20:4/20:4) levels in the activated cells was almost completely 
prevented when the cells were pretreated with either pyrrophenone or triacsin C, two 
potent and selective inhibitors of the arachidonate-releasing cPLA2α and arachidonoyl-
CoA synthetase, respectively. Previous data from our laboratory has demonstrated 
that, at the concentrations employed, these inhibitors effectively block the 
aforementioned enzyme activities while exerting no significant effect on other PLA2 or 
acyl-CoA synthetases [30, 34, 46, 47]. 
 
Factors regulating PI(20:4/20:4) production by macrophages – Fig. 3A shows that in 
addition to zymosan, other widely used macrophage stimuli also produced significant 
amounts of PI(20:4/20:4). Opsonized zymosan and the calcium ionophore A23187 were 
as potent as zymosan in inducing PI(20:4/20:4) formation. Bacterial lipopolysaccharide 
(LPS), platelet-activating factor (PAF), and phorbol myristate acetate (PMA) behaved as 
weak inducers of PI(20:4/20:4) formation, and ATP had no effect. Priming of the cells 
with LPS before stimulating the cells with the aforementioned agonists had no effect 
on PI(20:4/20:4) formation beyond what was already achieved with LPS alone. This is a 
striking finding, since stimulus-mediated cPLA2α activation and subsequent 20:4 
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mobilization in macrophages —an event that is necessary for PI(20:4/20:4) formation, 
as shown in Fig. 2C— was found to be noticeably increased by LPS priming (Fig. 3B-E), 
in agreement with previous reports [48]. Unlike free 20:4, PI(20:4/20:4) was totally 
retained by the cells after the zymosan stimulation (Fig. 3F). 
 To study whether the accumulation of PI(20:4/20:4) correlates with the 
intensity of 20:4 mobilization, the production of PI(20:4/20:4) was compared with that 
of free 20:4 in macrophages treated with different stimuli, including a combination of 
PMA and A23187 the latter two, which is known to synergistically activate cPLA2α and 
attendant 20:4 mobilization [4, 6, 23]. The data are shown in Fig. 3G, and indicate that, 
in general, the stimuli that mobilized more 20:4 also produced more PI(20:4/20:4). 
However,  the combination of PMA plus A23187 induced 3-4 times more free 20:4 than 
zymosan or A23187 alone, but the amounts of PI(20:4/20:4) produced under these 
conditions were all comparable. PAF and PMA, promoted little 20:4 release, but 
induced significant accumulation of PI(20:4/20:4) compared to control. (Fig. 3G). 
 
PI(20:4/20:4) formation during murine peritonitis – To study in vivo generation of 
PI(20:4/20:4), a well-characterized murine model of  zymosan-induced peritonitis was 
used [49]. Zymosan was administered i.p., peritoneal cells were collected at various 
time points, and PI(20:4/20:4) formation was measured. PI(20:4/20:4) levels increased 
linearly during the first hour, decreasing rapidly afterwards (Fig. 4). The time-course of 
PI(20:4/20:4) formation is remarkably similar to that previously observed when 
isolated macrophages were used (Fig. 2A). Fig. 4 also shows the levels of the major 
20:4-containing PI species, PI(18:0/20:4), which decreased with time, likely as a 
consequence of cPLA2α activation.   
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Studies adding exogenous PI(20:4/20:4) to the cells – The kinetics of formation of 
PI(20:4/20:4), both in vitro and in vivo, showing a rapid increase followed by a decrease 
is consistent with this molecule acting as an intracellular signaler. To study this 
possibility, PI(20:4/20:4) was introduced into the cells by complexing it with cationic 
carriers that counteract the negative charges of the phospholipid and make it 
permeable to the cell membrane [22, 50]. Using this procedure, we found that 35 ± 6% 
of the added phospholipid was incorporated into the cells during a 30-min incubation 
period (mean ± S.E.M., n=3). Interestingly, cells metabolized the incorporated 
PI(20:4/20:4) rapidly, degrading approximately 70 ± 10% of the phospholipid within 1 h 
(mean ± S.E.M., n=3). This is an important observation, since it shows that 
exogenously-added PI(20:4/20:4) behaves similar to that formed intracellularly (Fig. 
2A), which in turn suggests that the addition of exogenous PI(20:4/20:4) appropriately 
mirrors a physiologically-relevant condition.  
 To investigate the metabolism of PI(20:4/20:4) by the macrophages, we utilized  
phospholipids labeled with deuterium in the 20:4 moiety at either the sn-1 or sn-2 
positions, namely PI([2H]20:4/20:4) and PI(20:4/[2H]20:4). LC/MS analyses of 
deuterium-containing lipids at different times after exposure of the cells to these 
deuterium-labeled PI(20:4/20:4) molecules revealed no significant incorporation of 
label into any other cellular phospholipid species, thus suggesting that PI(20:4/20:4) is 
not an intermediate in the formation and/or replenishment of membrane phospholipid 
pools. Of note, no [2H]20:4-labeled lysoPI was detected under any condition tested, 
indicating that the loss of the two 20:4 moieties from PI(20:4/20:4) occurs either 
simultaneously or sequentially in such a rapid manner that a 20:4-containing lysoPI 
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intermediate does not accumulate. It is worth noting in this regard that the two major 
intracellular PLA2 present in cells, i.e. cPLA2α and group VIA PLA2, possess significant 
lysophospholipase activity [51], and thus both enzymes could degrade PI(20:4/20:4) 
without generating a lyso intermediate. 
 In contrast to the lack of deuterium label in phospholipid species, abundant 
label was detected in neutral lipids (triacylglycerol), when the cells were incubated 
with deuterium-labeled PI(20:4/20:4) at either the sn-1 or sn-2 positions. This is 
consistent with the notion that macrophages, as primary cells, have their 20:4 
phospholipid pools replete, and thus any excess of this fatty acid is stored in neutral 
lipids [10, 45]. 
 
Cellular role of PI(20:4/20:4) – Previous results have suggested that the choline 
phospholipid analogue of PI(20:4/20:4), i.e. PC(20:4/20:4), may serve a metabolic 
intermediary role, by constituting a rapid reacylation pool for free 20:4 once the level 
of this fatty acid raises within the cell. [44, 45]. Formation of PC(20:4/20:4) under these 
conditions occurs primarily via the de novo pathway of lipid synthesis [44,45]. To 
investigate whether this can also be a metabolic fate for PI(20:4/20:4), experiments 
were carried out in which macrophages were incubated with a high free 20:4 
concentration (20 µM, 10 min). The data indicated that PI(20:4/20:4) was indeed 
formed under these conditions as was, expectedly, PC(20:4/20:4). Confirming that 
production of these diarachidonoylated phospholipids most likely arises from the de 
novo pathway, the intermediates diarachidonoyl phosphatidic acid and diarachidonoyl 
glycerol were also readily detected under these conditions (data not shown). 
Previous results indicated that PC(20:4/20:4), may provide the 20:4 moiety 
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used for anandamide synthesis in rat brain [52]. To investigate whether PI(20:4/20:4) 
may serve a similar role, we used phospholipids labeled with deuterium in the 20:4 
moiety at either the sn-1 or sn-2 positions. After introducing the phospholipid into the 
cells, these were stimulated with zymosan for various periods of time, and anandamide 
synthesis was determined by LC/MS under the conditions described by Dennis and co-
workers [53]. We failed to detect deuterium-labeled anandamide at any condition 
tested up to 2 h incubation of the cells. Likewise, no water-soluble deuterium-
containing eicosanoid-like material could be identified by LC/MS. Collectively, these 
results indicate that, unlike PC(20:4/20:4), PI(20:4/20:4) does not provide 20:4 
moieties for the synthesis of anandamide or other bioactive lipid compounds in murine 
macrophages. 
 Recent results have shown that certain phospholipid species such as 
PC(16:0/18:1) or PC(12:0/12:0) have the capacity to regulate gene induction by 
modulating the activity of transcription factors [54, 55]. To evaluate whether 
PI(20:4/20:4) serves a similar biological function in macrophages, we studied by qPCR 
the possible effects of this phospholipid on the induction of a number of genes that are 
known to be involved in inflammation. The genes tested were: Arg1, Ccl2, Cox2, Fizz1, 
Il1b, Il6, Il10, Il12a, Il12b, Il23, Mrc1, Mrc2, Nos2, Tgfb, Tnfa, and Ym1. Of these, a 
strong upregulation of Il10, Cox2, Il23 and Tnfa was clearly detected in cells stimulated 
with zymosan, but addition of PI(20:4/20:4) to the cells failed to exert any effect, 
whether stimulatory or inhibitory, on the induction of all genes tested. Combinations 
of the phospholipid with zymosan did not produce any effect beyond what was already 
observed with zymosan alone (Fig. 5).  
 The inability of PI(20:4/20:4) to regulate long-term responses such as gene 
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transcription in macrophages, prompted us to investigate possible effects of the 
phospholipid on immediate responses. Among those, generation of reactive oxygen 
species such as superoxide anion and hydrogen peroxide is a critical response of 
macrophages for pathogen killing and maintaining efficient host defense [56]. The 
effect of PI(20:4/20:4) on superoxide anion production by the macrophages is shown in 
Fig. 6A. There was a tendency for PI(20:4/20:4) to induce superoxide anion when 
added alone to the cells, but it did not reach statistical significance. However, 
PI(20:4/20:4) did significantly enhance the responses to both PMA and zymosan. In 
these experiments, PI(20:4/20:4) was added 30 min before either PMA or zymosan. As 
a control of these experiments, we used a PI extract from bovine liver (Sigma; 
consisting primarily of  species PI(18:0/20:4), PI(18:0/20:3), PI(18:1/18:1), and 
PI(18:0/18:1), as assessed by LC/MS. 20:4 comprised 20-25% of total fatty acids in this 
liver PI extract, and no PI(20:4/20:4) was found in it). Under the same conditions as 
those used for PI(20:4/20:4), liver PI had no effect on superoxide production under any 
condition tested, highlighting the specificity of action of PI(20:4/20:4) (Fig. 6A). When 
zymosan and PMA were added to the cells 2 h after addition of PI(20:4/20:4), —a time 
long enough  to  allow  the  cells  to  completely metabolize the phospholipid (vide 
supra)—, the enhancing effect of PI(20:4/20:4) was no longer observed (data not 
shown). 
 To further delineate the effect of PI(20:4/20:4) on innate immune responses, 
we next measured lysozyme secretion by macrophages treated or not with the 
phospholipid.  Lysozyme hydrolyzes a specific glycoside bond in the peptidoglycan that 
forms bacterial cell walls, thereby constituting a key component of innate immune 
defense against bacterial infection [57]. While PI(20:4/20:4) did not show a measurable 
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effect on its own on lysozyme secretion, it did significantly enhanced lysozyme 
secretion by activated macrophages, and this effect was not mimicked by the liver PI 
extract used as a control (Fig. 6B).  
 
Discussion 
LC/MS provides a comprehensive frame for the analysis of  changes in the composition 
of unique glycerophospholipid species present in cells [9, 25]. Here we have applied 
this technology to study changes in the levels of all major 20:4-containing 
glycerophospholipids of murine macrophages responding to zymosan. Our results 
show that the major phospholipid species for 20:4 mobilization in zymosan-stimulated 
macrophages are PC (all major species) and PI (largely the species PI(18:0/20:4)), with 
little contribution from PS species and virtually no contribution from any PE species. It 
is interesting to note that among the major contributors to 20:4 release, the percent 
hydrolysis was very similar, i.e. irrespective of their relative mass levels, all these 
species are consistently hydrolyzed by 50-55%. These findings are fully consistent with 
the notion that it is the presence of 20:4 at the sn-2 position of phospholipids, not the 
substituent and type of linkage (acyl-, alkyl- or alkenyl-) at the sn-1 position that 
determines their hydrolysis by cPLA2α [45, 51]. 
 The lack of contribution of any PE species, which collectively constitute the 
major reservoir of intracellular 20:4 in these cells is striking. In this regard, it should be 
noted that in our experiments, the levels of 20:4-containing phospholipids are 
measured after zymosan challenge, which represents a balance between what is 
released by phospholipases –minus what is reincorporated back into phospholipids by 
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the highly active CoA-dependent acyltransferases present in these cells [10, 45]. Thus, 
the lack of net release of 20:4 from PE species might not necessarily reflect that these 
phospholipids are not substrates for the release but rather that, once attacked by 
cPLA2α they are rapidly reformed/replenished via the concerted action of CoA-
dependent acyltransferases and CoA-independent transacylases.  
 Of all the 20:4-containing species measured, only two of them, namely 
PC(20:4/20:4) and PI(20:4/20:4) increased their levels after zymosan stimulation. The 
stimulated production of the two species was almost completely prevented by treating 
the cells with the cPLA2α and arachidonoyl-CoA synthetase inhibitors pyrrophenone 
and triacsin C, suggesting that both compounds are formed via CoA-dependent 
reacylation reactions, in which the 20:4 acting as a donor arises from the cPLA2α-
mediated hydrolysis of other 20:4-containing glycerophospholipids.  
 While previous studies have focused on the formation and possible biological 
roles of PC(20:4/20:4) in cells [44, 52], with the exception of our own recent work 
identifying PI(20:4/20:4) as a minor 20:4-containing phospholipid of human monocytes 
[29, 30], to the best of our knowledge we are not aware of previous studies dealing 
with this relatively uncommon species. By using a metabolipidomic approach 
consisting in stimulating the cells with zymosan in the presence of a low dose of 
[2H]20:4 to “trap” possible intermediates, we studied in detail the route of biosynthesis 
of PI(20:4/20:4). Two main pathways exist for the incorporation of 20:4 in 
phospholipids. These are  the de novo pathway for phospholipid biosynthesis and the 
Lands cycle of  phospholipid deacylation/reacylation [10, 44]. In the Lands cycle, a 
preformed phospholipid is acted upon by intracellular phospholipases of the A-type to 
generate a 1- or 2-lysophospholipid that can be reacylated with 20:4 by the action of 
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CoA-dependent acyl transferases. A major difference between the de novo route and 
the Lands cycle is that the latter, but not the former, is sensitive to PLA2 inhibitors. 
Thus the results showing that PI(20:4/20:4) is strongly sensitive to inhibition of the 
signal-activated cPLA2α by pyrrophenone are fully consistent with the Lands pathway 
being the major route of biosynthesis for this compound.  
 From our metabolipidomic experiments further mechanistical considerations 
can be made, as follows: (i) the finding that not one but two species of deuterium-
labeled PI(20:4/20:4), namely PI([2H]20:4/[2H]20:4) and PI([2H]20:4/20:4), are detected 
indicates that, if the PI molecule already contains 20:4 in the sn-2 position, recycling 
only takes place at the sn-1 position; (ii) the finding that if a PI molecule contains only 
one 20:4 moiety, it is invariably found at the sn-2 position, suggests that recycling at 
the sn-1 position with 20:4 only takes place if the sn-2 position is already occupied by 
20:4; and (iii) the conspicuous absence of deuterium-containing lysoPI suggests that 
incorporation of a second 20:4 molecule proceeds at a very high rate, thus lyso 
intermediates do not accumulate. Collectively, these considerations prompt us to 
propose a sequential mechanism for PI(20:4/20:4) synthesis in activated cells, whereby 
a preformed PI molecule is first acted upon by cPLA2α —and perhaps also by other 
intracellular PLA2 [58-60]— to generate a 2-lysoPI. This 2-lysoPI will be rapidly 
reacylated with 20:4 before a phospholipase A1 attacks the newly-formed 20:4-
containing PI to produce 1-lysoPI that will be reacylated again with 20:4 to form 
PI(20:4/20:4). From this model, it can be predicted that the phospholipase A1 activity 
participating in this sequence of events shows specificity for PI molecules containing 
20:4 at the sn-2 position. An enzyme with such an exquisite selectivity could constitute 
an excellent target for pharmacologic control of PI(20:4/20:4) formation, and we have 
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initiated studies aimed at characterizing it in macrophages. 
 The rapid rate of formation of PI(20:4/20:4) in zymosan-stimulated cells and its 
cellular retention suggest that this molecule may play a role in regulating cell signaling 
events. Moreover, increased PI(20:4/20:4) formation is shown to be of 
pathophysiological significance since it is also detected in vivo during murine 
peritonitis. To define the biological roles of PI(20:4/20:4) we devised strategies for 
introducing this phospholipid in cells. We achieved success in this regard by complexing 
the phospholipid with the cationic carrier protein histone H1, adapting protocols 
originally described by Prestwitch and co-workers [50] for the introduction of 
polyphosphoinositides in cells.  
 Considerable evidence has accumulated over the years to indicate that cPLA2α 
and attendant 20:4 mobilization are involved in the activation of the NADPH oxidase 
complex of phagocytes [61]. The NADPH oxidase is a multicomponent electron 
transport chain that transfers electrons from NADPH to molecular oxygen to generate 
superoxide anion, a critical step for pathogen killing and the maintenance of efficient 
host defense [56]. Activation of the oxidase involves assembly of the membrane 
component flavocytochrome b558 (consisting of gp91phox and p22 phox), with the 
cytosolic components p67phox, p47phox, p40phox, and the small guanosine 5’-
triphosphate-binding protein Rac-1 [56].  While the exact target sites for 20:4 on the 
assembled NADPH are not known, there is evidence that the fatty acid  serves a role in 
activating the oxidase after the assembly of the oxidase complex has taken place [61]. 
Much of the evidence implicating 20:4 in these events has been obtained from studies 
adding the fatty acid exogenously to the cells and/or by inhibiting cPLA2α activity by 
different means. However, conclusions drawn from this type of studies have 
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sometimes yielded conflicting results and are complicated by the lack of knowledge of 
the molecular mechanism through which 20:4 mediates these activating functions.  
 Given that 20:4 incorporates very rapidly into various phospholipids in activated 
cells [9, 10, 46], the possibility exists that at least part of the effects on innate immune 
responses observed when 20:4 is added to the cells may be mediated by its 
incorporation into discrete phospholipid species such as PI(20:4/20:4), which would be 
the actual molecular entity that carries biological activity. In analogy with this idea, it 
has recently been reported that some of the stimulatory effects of exogenous 
palmitoleic acid on murine fibroblast-like cell lines might be due not to the fatty acid 
itself but to the fatty acid accumulating into phosphatidylinositol species [62]. 
Moreover, pharmacological manipulations that lead to inhibition of PI(20:4/20:4) 
production such as use of pyrrophenone or triacsin C, are long known to strongly blunt 
NADPH oxidase activation and superoxide anion generation in receptor-activated cells 
[61, 63]. Because triacsin C acts to prevent incorporation of 20:4 into phospholipids, 
this inhibitor would not be expected to blunt NADPH oxidase activation if the activating 
stimulus was primarily the exogenous free 20:4 [63].  
 The activating effect of PI(20:4/20:4) on superoxide anion production and 
lysozyme secretion appears to be specific for this particular phospholipid, since 
addition of a mixture of PI species from bovine liver —in which 20:4 makes up for 20-
25% of total fatty acid, and no PI(20:4/20:4) is present— does not reproduce the 
stimulatory effects of PI(20:4/20:4).  These findings raise the intriguing question of how 
much of the biological activity of PI(20:4/20:4) is related to the presence of two 
arachidonyl residues. This is an interesting concept, since the structurally related and 
much more studied analogue PC(20:4/20:4) has been found to serve primarily a 
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metabolic role, both as a ‘defensive’ means for the cells to protect themselves from 
the excessive availability of exogenous free 20:4 [44, 45], and as a 20:4 donor for 
anandamide synthesis under certain conditions [52]. According to the data reported 
herein, the former role but not the latter may also be served by PI(20:4/20:4).  It is also 
noteworthy that, despite PE being the major 20:4-containing class in macrophages and 
in phagocytic cells in general, these cells do not appear to synthesize PE(20:4/20:4). 
We have consistently failed to detect such a species under a variety of conditions and 
utilizing different types of phagocytic cells [30-34], and to the best of our knowledge, 
we are not aware of studies by other groups documenting the formation of 
PE(20:4/20:4). Taken together, we speculate that not only the presence of the two 20:4 
residues but likely also the polar headgroup may be a key determinant of the biological 
activity associated to PI(20:4/20:4).  
  In summary, we conclude that comprehensive profiling of 20:4-containing 
phospholipids by LC/MS during zymosan phagocytosis has uncovered an unexpected 
role for a discrete phospholipid species, PI(20:4/20:4), in regulating innate immune 
responses. Our studies suggest that this phospholipid adds to the growing family of 
lipids with active roles in cell signaling.  
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Figure Legends 
 
Figure 1. 20:4-containing phospholipid species in murine peritoneal macrophages and 
the effect of zymosan stimulation. A) The profile of 20:4-containing PC (black), PE (dark 
gray),  PI (white), and PS (gray) species in unstimulated cells was determined by LC/MS. 
B) 20:4 content in phospholipids as shown by class. C) 20:4 remaining in phospholipid 
species after a 1-h stimulation with 1 mg/ml zymosan. The 100% corresponds to the 
levels of each species, as shown in panel A.  D)  20:4 remaining in phospholipids after a 
1-h stimulation with 1 mg/ml zymosan as shown by class.  Data are shown as means ± 
S.E.M. of five independent determinations. 
 
Figure 2. Stimulated production of PI(20:4/20:4) in murine macrophages. A) Time-
course of PI(20:4/20:4) formation after zymosan stimulation. The cells were activated 
with 1 mg/ml zymosan for different times. After lipid extraction, PI(20:4/20:4) levels 
were determined by LC/MS. B) Detection of deuterium-labeled PI(20:4/20:4) in 
macrophages. The cells were exposed to 1 µM [2H]20:4 at the time they were 
stimulated with 1 mg/ml zymosan for 1 h. The figure shows the isotopic distribution of 
the two deuterium-labeled PI(20:4/20:4) species detected by LC/MS, namely 
PI([2H]20:4/20:4) (set of peaks with a maximum at m⁄z 913.6) and PI([2H]20:4/[2H]20:4) 
(set of peaks with a maximum at m⁄z 920.6). C) Generation of PI(20:4/20:4) after 
zymosan stimulation requires cPLA2α and CoA-dependent acyl transferases. The cells 
were treated with 1 µM pyrrophenone (Pyrr), 3 μM triacsin C or neither (none), as 
indicated for 30 min. Afterward, the cells were stimulated (gray bars) or not (open 
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bars) with 1 mg/ml  zymosan for 60 min. Data are given as means ± S.E.M. of three 
independent experiments. 
 
Figure 3. Generation of PI(20:4/20:4) in response to stimuli. A) The macrophages were  
 treated with the stimuli listed for 1 h at the following concentrations: 100 nM PAF, 100 
ng/ml PMA, 100 µM ATP, 1 µM calcium ionophore A23187, 1 mg/ml zymosan or 1 
mg/ml opsonized zymosan (OpZym) (open bars). In parallel experiments the cells were 
pretreated with 100 ng/ml LPS for 60 min before addition the aforementioned stimuli 
at the indicated concentrations (closed bars). B-E) LPS priming enhances zymosan-
stimulated 20:4 mobilization from macrophages. The cells were either untreated (Ctrl) 
or treated with 1 mg/ml zymosan (Zym) for 1 h, or LPS plus zymosan (1 h with 100 
ng/ml LPS followed by 1 h with 1 mg/ml zymosan). Afterward, the cellular content of 
20:4-containing PC (B), 20:4-containing PE (C), 20:4-containing PI (D), or 20:4-
containing PS (E) was determined by LC/MS. F) PI(20:4/20:4) is associated with cells 
and not released after cell activation. The cells were stimulated with 1 mg/ml zymosan 
for 1 h. Afterward, total content of PI(20:4/20:4) (open bars) and 20:4 (stripped bars) in 
cells or supernatants was determined by LC/MS or GC/MS, respectively. G) Comparison 
between the amounts of 20:4 and PI(20:4/20:4) produced by macrophages responding 
to various stimuli. The cells were treated with the stimuli listed at the following 
concentrations: 100 nM PAF, 100 ng/ml PMA, 1 µM A23187, 1 mg/ml zymosan, or 100 
ng/ml PMA plus 1 µM A23187 for 60 min. Afterward, total content of 20:4 (black bars) 
and PI(20:4/20:4) (gray bars) was determined by GC/MS or LC/MS, respectively. Data 
are given as means ± S.E.M. of three independent experiments. 
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Figure 4. PI(20:4/20:4) is formed in vivo during murine peritonitis. Zymosan (1 mg in 
500 µl sterile PBS) or control vehicle was injected i.p. to the mice. Peritoneal lavage 
was collected at different times, and the cells were isolated by centrifugation. After 
lipid extraction, PI(20:4/20:4) and PI(18:0/20:4) levels were determined by LC/MS. Data 
are given as means ± S.E. of three independent experiments, each utilizing 2 different 
animals per condition. 
 
 
Figure 5. PI(20:4/20:4) does not regulate the expression of inflammatory genes in 
macrophages. The cells were treated with 10 µM PI(20:4/20:4), 1 mg/ml zymosan, both 
or neither (Control) as indicated for 6 h. Afterward, the expression of Il10, Cox2, Il23, 
and Tnfa genes was studied by qPCR. Data are from an experiment with triplicate 
determinations (means ± S.E.M.) that is representative of 3 independent experiments. 
 
Figure 6. PI(20:4/20:4) regulates superoxide production (A) and lysozyme secretion (B) 
in macrophages. Superoxide anion and lysozyme were measured in control cells or cells 
treated with the stimuli listed (100 ng/ml PMA, 1 mg/ml zymosan) that had been 
incubated previously with PI(20:4/20:4) (closed bars), bovine liver PI extract (gray bars) 
or neither (open bars) for 30 min. Data are given as means ± S.E.M. of three 
independent experiments. *, significantly different (p < 0.05) from their respective 
controls.  
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